China Shenghuo Pharmaceutical (KUN)
China Shenghuo Pharmaceutical Revenue Growth: 37.97%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
KUN Revenue Growth Rankings
| Overall | 89th percentile | 479 of 4364 |
| Sector | 80th percentile | 87 of 456 in Healthcare |
| Industry | 83rd percentile | 3 of 18 in Drug Manufacturers - Major |
KUN Revenue Growth Range, Past 5 Years
| Minimum | -19.01% | Sep 2010 |
| Maximum | 73.30% | Sep 2008 |
| Average | 21.94% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these KUN related companies
KUN News
URGENT: $KUN filed to delay releasing quarterly earnings results (SEC Filing Form NT 10Q) http://stks.co/3pg2
about 15 days ago by MarketBrief
about 15 days ago by MarketBrief
Ceradyne, San Juan Basin Royalty Among Stocks falling to Annual Lows Wednesday
Apr 25, 4:32PM Fox Business
Apr 25, 4:32PM Fox Business
China Shenghuo Pharmaceutical Receives Opinion with Going Concern Qualification from its Auditor
Apr 05, 9:00PM PR Newswire
Apr 05, 9:00PM PR Newswire
China Shenghuo Pharmaceutical Reports Financial Results for the Full Year 2011
Mar 30, 2:09PM PR Newswire
Mar 30, 2:09PM PR Newswire
China Shenghuo Pharmaceutical Reports Financial Results for the Third Quarter of 2011
Nov 14, 4:17PM PR Newswire
Nov 14, 4:17PM PR Newswire
China Shenghuo Pharmaceutical Holdings, Inc. Reports Financial Results for the Second Quarter of 2011
Aug 16, 12:31AM PR Newswire
Aug 16, 12:31AM PR Newswire
China Shenghuo Pharmaceutical Reports Financial Results for the First Quarter of 2011
May 16, 9:00PM PR Newswire
May 16, 9:00PM PR Newswire
China Shenghuo Pharmaceutical Reports Financial Results for the Full Year 2010
Mar 30, 8:30PM PR Newswire
Mar 30, 8:30PM PR Newswire
China Shenghuo Pharmaceutical's Lixuwang Trademark Awarded Chinese Well-Known Trademark Honor
Jan 24, 2:45AM PR Newswire
Jan 24, 2:45AM PR Newswire
$KUN is up .40 on no news the stock trading on a volume of 450k and has a new 52 week high
about 498 days ago by latestbusinessn
about 498 days ago by latestbusinessn
$ONP risk reward is huge .How many of these China pumps have we seen blowup.I had 2 a couple years ago $KUN and China Lighting
about 698 days ago by Detroitblues
about 698 days ago by Detroitblues
$SQNM overnight gapper on ridiculous move, also watching $KUN closely which looks like controlled buying
about 1086 days ago by SoberStocks
about 1086 days ago by SoberStocks
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| KUN | 0.1428 | +0.00 | +0.00% | 2.810M |
| KUB | 41.97 | +0.05 | +0.12% | 10.53B |
| KTOS | 5.395 | -0.14 | -2.44% | 179.61M |
| KTF | 14.36 | +0.08 | +0.56% | |
| KTEC | 9.75 | -0.19 | -1.91% | 53.18M |
| KTCC | 10.51 | -0.21 | -1.96% | 112.02M |
| KT | 11.73 | -0.11 | -0.93% | 5.761B |
| KSWS | 2.76 | +0.01 | +0.36% | 97.90M |
| KSW | 3.89 | -0.06 | -1.52% | 24.78M |
| KSU | 64.33 | -2.31 | -3.47% | 7.328B |
